Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit
October 06 2020 - 5:17PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that John Houston, Ph.D.,
President and Chief Executive Officer, will present a keynote
plenary session at the 3rd Annual Targeted Protein Degradation
Summit being held virtually October 14-15, 2020. The presentation
will reflect on Arvinas’ advances in its PROTAC® platform and
introduce new pipeline programs.
Presentation Details:
Title: The Promise of PROTAC® Protein
Degraders: What’s Next for Arvinas’ Pipeline &
PlatformDate: Wednesday, October 14,
2020Time: 11:30 a.m. ET
About ArvinasArvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary technology platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. The company has two clinical-stage programs: ARV-110 for
the treatment of men with metastatic castrate-resistant prostate
cancer; and ARV-471 for the treatment of patients with locally
advanced or metastatic ER+/HER2- breast cancer. For more
information, visit www.arvinas.com.
Contacts for Arvinas
InvestorsWill O’Connor, Stern
Investor Relationsir@arvinas.com
MediaKirsten Owens, Arvinas
Communicationskirsten.owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Sep 2023 to Sep 2024